Finanzas de Monte Rosa Therapeutics Inc (GLUE)GLUEMonte Rosa Therapeutics Inc

Evaluating the bottom line, Monte Rosa Therapeutics, Inc. maintains a gross margin of 100.00%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -547.84%, while the net margin is -483.91%. These profitability ratios, combined with a Return on Equity (ROE) of -42.66%, provide a clear picture of how effectively GLUE converts its operational activities into shareholder value.

In the context of the broader market, GLUE competes directly with industry leaders such as ODTX and KURA. With a market capitalization of $969.16M, it holds a leading position in the sector. When comparing efficiency, GLUE's gross margin of 100.00% stands against ODTX's N/A and KURA's 98.84%. Such benchmarking helps identify whether Monte Rosa Therapeutics, Inc. is trading at a premium or discount relative to its financial performance.

Monte Rosa's total revenue for Q1 2026 was $4.21 million, but it has faced significant net losses, with a net income of -$44.5 million for the same quarter. The gross margin remains strong at 100%, indicating efficient cost management despite revenue challenges.